1.81

0.56% +0.01

Vor Biopharma Inc (VOR)

Overview News Price History Option Chain Financials Discussions Forecast

Vor Biopharma Inc stock is currently priced at $1.81, with a 24-hour trading volume of 167.07K. It has seen a +0.56% increased in the last 24 hours and a +4.62% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.78 pivot point. If it approaches the $1.89 resistance level, significant changes may occur.

Previous Close:

$1.80

Open:

$1.82

24h Volume:

167.07K

Market Cap:

$123.55M

Revenue:

Net Income/Loss:

$-115.51M

P/E Ratio:

-0.8916

EPS:

-2.03

Net Cash Flow:

$-95.89M

1W Performance:

+5.85%

1M Performance:

+4.62%

6M Performance:

+2.84%

1Y Performance:

-59.87%

1D Range:

$1.7346

$1.85

52W Range:

$1.62

$5.70

Vor Biopharma Inc Stock (VOR) Company Profile

Name

Vor Biopharma Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

617 655 6580

Address

100 Cambridgepark Drive, Suite 400, Cambridge

Employee

Twitter

Next Earnings Date

2024-05-23

Latest SEC Filings

VOR's Discussions on Twitter

Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-26-22	Initiated	Wedbush	Outperform
Apr-27-22	Initiated	Goldman	Neutral
Dec-17-21	Initiated	H.C. Wainwright	Buy
Dec-03-21	Initiated	Robert W. Baird	Outperform
Dec-02-21	Initiated	Oppenheimer	Outperform
Oct-19-21	Initiated	JMP Securities	Mkt Outperform
Mar-25-21	Initiated	B. Riley Securities	Buy
Mar-03-21	Initiated	Barclays	Overweight
Mar-03-21	Initiated	Evercore ISI	Outperform
Mar-02-21	Initiated	Goldman	Sell
Mar-02-21	Initiated	Stifel	Buy

View All

Vor Biopharma Inc Stock (VOR) Latest News

Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock - MSN

MSN

Does Vor Biopharma (VOR) Have the Potential to Rally 186% as Wall Street Analysts Expect? - Yahoo New Zealand News

Yahoo New Zealand News

Vor Biopharma (NYSE:VOR) Stock Rating Reaffirmed by Oppenheimer - Defense World

Defense World

Vor Biopharma (NYSE:VOR) Stock Rating Reaffirmed by Wedbush - Defense World

Defense World

Vor Biopharma Inc. to Post FY2028 Earnings of $0.71 Per Share, HC Wainwright Forecasts (NYSE:VOR) - MarketBeat

MarketBeat

Vor Biopharma's (VOR) Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat

MarketBeat

Vor Biopharma Inc Stock (VOR) Financials Data

Vor Biopharma Inc (VOR) Net Income 2024

VOR net income (TTM) was -$115.51 million for the quarter ending September 30, 2023, a -33.64% decrease year-over-year.

Vor Biopharma Inc (VOR) Cash Flow 2024

VOR recorded a free cash flow (TTM) of -$95.89 million for the quarter ending September 30, 2023, a -2.34% decrease year-over-year.

Vor Biopharma Inc (VOR) Earnings per Share 2024

VOR earnings per share (TTM) was -$1.89 for the quarter ending September 30, 2023, a +17.83% growth year-over-year.

Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.